In Vitro: Anagrelide potently inhibits the development of marrow megakaryocytes (IC50=26 nM). Anagrelide (0.05, 0.3, 1 µM; 12-day) inhibits only megakaryocytic cell growth not non-megakaryocytic cells. Anagrelide (0.1-10000 nM) induces a cytotoxic effect in the GIST882 cell line.
In Vivo: Anagrelide (5 mg/kg/bid; for 10 days) inhibits or reduces tumor growth in GIST2B, GIST9, GIST882 model models.